On Monday, Geron Corporation (NASDAQ:GERN)’s shares inclined 13.59% to $5.10.
GERN has the market capitalization of $710.42 million. The stock has P/B ratio of -5.43 while EPS was $-0.01. Institutional ownership of the company was 45.60% while 1.58.22 million shares were outstanding. Net profit margin of the Company was -1.10%. Share of the company moved above its SMA 50 with 45.76%. ROE ratio was -0.30% while ROI was -27.80%. The mean estimate for the short term price target for Geron Corporation (NASDAQ:GERN) stands at $5.50 according to 3 Analysts. The higher price target estimate for the stock has been calculated at $6.00 while the lower price target estimate is at $5.00. Geron Corporation (NASDAQ:GERN) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology.
Target Corporation (NYSE:TGT)’s shares dropped -1.28% to $72.50.
TGT has market capitalization of $45.24 billion. Its current ratio was 1.10 while its shares were below its 50 days simple moving average with -4.16%. The company offered earning per share of $4.46 while its 616.05 million shares were outstanding. YTD performance of the company was -4.49%. Stock volatility for the week was 1.86% while for the month it was shown at 2.58%. The mean estimate for the short term price target for Target Corporation (NYSE:TGT) stands at $82.62 according to 21 Analysts. The higher price target estimate for the stock has been calculated at $92.00 while the lower price target estimate is at $72.00. Target Corporation (NYSE:TGT) is engaged in providing everyday essentials and fashionable, and differentiated merchandise at discounted prices. The Company offers its products through stores, online or through mobile devices. The Company sells an assortment of general merchandise and food through its store and digital channels.
At the end of Monday’s trade, Biogen Inc (NASDAQ:BIIB)‘s shares dipped -2.17% to $286.86.
So far in 2015, the company has a year-to-date performance of -15.49%. The stock, as of last close, traded 12.94% up from its 52 week low and was -40.26% below its 52 week high. Its latest closing price was -19.77% below the SMA200 while the distance from SMA 50 and SMA 20 was 0.44% and -1.79% respectively. The mean estimate for the short term price target for Biogen Inc (NASDAQ:BIIB) stands at $364.36 according to 14 Analysts. The higher price target estimate for the stock has been calculated at $450.00 while the lower price target estimate is at $266.00. Biogen Inc (NASDAQ:BIIB) is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.